Sirolimus-Induced Remission of Posttransplantation Lymphoproliferative Disorder
Authors:
- Brett CullisBCBrett Cullis
- Richard D’sOuzaRDRichard D’sOuza
- Paul McCullaghPMPaul McCullagh
- Simon HarriesSHSimon Harries
- Anthony NichollsANAnthony Nicholls
- Richard LeeRLRichard Lee
- Coralie BinghamCBCoralie Bingham
- 1 May 2006
- journal article
- case report
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 47 (5) , e67-e72
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimusNephrology Dialysis Transplantation, 2005
- Sirolimus for Kaposi's Sarcoma in Renal-Transplant RecipientsNew England Journal of Medicine, 2005
- Rapid response to rituximab in a pediatric liver transplant recipient with post‐transplant lymphoproliferative disease and maintenance with sirolimus monotherapyPediatric Transplantation, 2005
- Sirolimus for pediatric liver transplant recipients with post‐transplant lymphoproliferative disease and hepatoblastoma*Pediatric Transplantation, 2004
- Rapamycin is active against B-precursor leukemiain vitroandin vivo, an effect that is modulated by IL-7-mediated signalingProceedings of the National Academy of Sciences, 2003
- Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting dosesTransplantation, 2003
- Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatmentTransplant International, 2003
- RAPAMYCIN, A POTENT IMMUNOSUPPRESSIVE DRUG, CAUSES PROGRAMMED CELL DEATH IN B LYMPHOMA CELLSTransplantation, 1995
- Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant RecipientsNew England Journal of Medicine, 1990
- Expression of Interleukin-10 Activity by Epstein-Barr Virus Protein BCRF1Science, 1990